These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18221173)

  • 1. Monoclonal antibodies against viruses and bacteria: a survey of patents.
    Xiao X; Dimitrov DS
    Recent Pat Antiinfect Drug Discov; 2007 Nov; 2(3):171-7. PubMed ID: 18221173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses.
    Zhu Z; Dimitrov AS; Chakraborti S; Dimitrova D; Xiao X; Broder CC; Dimitrov DS
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):57-66. PubMed ID: 16441209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
    Groothuis JR; Nishida H
    Pediatr Int; 2002 Jun; 44(3):235-41. PubMed ID: 11982888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in the development and approval of monoclonal antibodies for viral infections.
    Reichert JM
    BioDrugs; 2007; 21(1):1-7. PubMed ID: 17263584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
    DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
    J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways.
    Piedimonte G; King KA; Holmgren NL; Bertrand PJ; Rodriguez MM; Hirsch RL
    Pediatr Res; 2000 Mar; 47(3):351-6. PubMed ID: 10709734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV.
    Pollack P; Groothuis JR
    J Infect Chemother; 2002 Sep; 8(3):201-6. PubMed ID: 12373481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palivizumab in the prevention of respiratory syncytial virus disease.
    Krilov LR
    Expert Opin Biol Ther; 2002 Oct; 2(7):763-9. PubMed ID: 12387675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiviral humanized and human monoclonal antibodies].
    Lashkevich VA
    Vopr Virusol; 2011; 56(5):4-8. PubMed ID: 22171470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.
    Wu H; Pfarr DS; Losonsky GA; Kiener PA
    Curr Top Microbiol Immunol; 2008; 317():103-23. PubMed ID: 17990791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
    Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
    J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model.
    Ottolini MG; Curtis SR; Mathews A; Ottolini SR; Prince GA
    Bone Marrow Transplant; 2002 Jan; 29(2):117-20. PubMed ID: 11850705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies in infectious diseases: clinical pipeline in 2011.
    Ter Meulen J
    Infect Dis Clin North Am; 2011 Dec; 25(4):789-802. PubMed ID: 22054756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of antiviral resistance across acute and chronic viral infections.
    Mason S; Devincenzo JP; Toovey S; Wu JZ; Whitley RJ
    Antiviral Res; 2018 Oct; 158():103-112. PubMed ID: 30086337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recombinant monoclonal antibodies for the treatment and prevention of viral infections].
    Al'khovskiĭ SV
    Vestn Ross Akad Med Nauk; 2011; (5):49-53. PubMed ID: 21786598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo selection of respiratory syncytial viruses resistant to palivizumab.
    Zhao X; Sullender WM
    J Virol; 2005 Apr; 79(7):3962-8. PubMed ID: 15767398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synagis: an anti-RSV monoclonal antibody.
    Driver LC; Oertel MD
    Pediatr Nurs; 1999; 25(5):527-30. PubMed ID: 12024401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.